BRCA2 Breakthrough: AI-Powered ‘Cancer Vaccine’ Enters Human Trials, Could Slash Breast Cancer Recurrence by 90%
Los Angeles, CA – A decade from now, the world may look back on today as the day breast cancer treatment was reinvented. A team of bioengineers at Stanford and UCLA has just launched Phase I human trials for a revolutionary, personalized mRNA vaccine that uses a patient’s own tumor DNA to train immune cells to hunt down and destroy residual breast cancer cells. Unlike traditional vaccines that prevent disease, this “therapeutic vaccine” is designed for women already diagnosed, targeting the unique genetic mutations of their specific triple-negative or BRCA-related breast cancers. In pre-clinical models, the vaccine—delivered via a painless micro-needle patch—eliminated any sign of recurrence in 90% of subjects within two years. The technology suggests that by 2034, annual booster shots could replace toxic chemotherapy cycles, transforming breast cancer into a manageable, chronic condition rather than a life-threatening crisis. The first patients are now being dosed, with early data expected by summer 2025.